These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24709328)

  • 1. Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2'-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles.
    Peng L; Feng L; Yuan H; Benhabbour SR; Mumper RJ
    Nanomedicine; 2014 Oct; 10(7):1497-506. PubMed ID: 24709328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oil-filled lipid nanoparticles containing 2'-(2-bromohexadecanoyl)-docetaxel for the treatment of breast cancer.
    Feng L; Benhabbour SR; Mumper RJ
    Adv Healthc Mater; 2013 Nov; 2(11):1451-7. PubMed ID: 23606545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model.
    Peng L; Schorzman AN; Ma P; Madden AJ; Zamboni WC; Benhabbour SR; Mumper RJ
    Int J Nanomedicine; 2014; 9():3601-10. PubMed ID: 25114529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical validation of orthotopically-implanted pulmonary tumor by imaging with 18F-fluorothymidine-positron emission tomography/computed tomography.
    Fushiki H; Miyoshi S; Noda A; Murakami Y; Sasaki H; Jitsuoka M; Mitsuoka K; Matsunari I; Nishimura S
    Anticancer Res; 2013 Nov; 33(11):4741-9. PubMed ID: 24222108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and optimization of oil-filled lipid nanoparticles containing docetaxel conjugates designed to control the drug release rate in vitro and in vivo.
    Feng L; Wu H; Ma P; Mumper RJ; Benhabbour SR
    Int J Nanomedicine; 2011; 6():2545-56. PubMed ID: 22072889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases.
    Sambade M; Deal A; Schorzman A; Luft JC; Bowerman C; Chu K; Karginova O; Swearingen AV; Zamboni W; DeSimone J; Anders CK
    Nanomedicine (Lond); 2016 Aug; 11(15):1947-55. PubMed ID: 27456556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
    Pectasides D; Pectasides M; Farmakis D; Kostopoulou V; Nikolaou M; Gaglia A; Koumpou M; Mylonakis N; Xiros N; Economopoulos T; Raptis SA
    Ann Oncol; 2005 Feb; 16(2):294-9. PubMed ID: 15668287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival.
    Whitehead CM; Earle KA; Fetter J; Xu S; Hartman T; Chan DC; Zhao TL; Piazza G; Klein-Szanto AJ; Pamukcu R; Alila H; Bunn PA; Thompson WJ
    Mol Cancer Ther; 2003 May; 2(5):479-88. PubMed ID: 12748310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).
    Gervais R; Ducolone A; Breton JL; Braun D; Lebeau B; Vaylet F; Debieuvre D; Pujol JL; Tredaniel J; Clouet P; Quoix E
    Ann Oncol; 2005 Jan; 16(1):90-6. PubMed ID: 15598944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: optimization and in vitro, in vivo evaluation.
    Chen L; Sha X; Jiang X; Chen Y; Ren Q; Fang X
    Int J Nanomedicine; 2013; 8():73-84. PubMed ID: 23319859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive monitoring of anticancer effects of cisplatin on lung cancer in an orthotopic SCID mouse model using [¹⁸F] FDG PET-CT.
    Mokhtar M; Kondo K; Takizawa H; Ohtani T; Otsuka H; Kubo H; Kajiura K; Nakagawa Y; Kawakami Y; Yoshida M; Fujino H; Sakiyama S; Tangoku A
    Oncol Rep; 2014 May; 31(5):2007-14. PubMed ID: 24604559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
    Tang N; Zhang Q; Fang S; Han X; Wang Z
    Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel-loaded PEG-albumin nanoparticles with improved antitumor efficiency against non-small cell lung cancer.
    Jin G; Jin M; Jin Z; Gao Z; Yin X
    Oncol Rep; 2016 Aug; 36(2):871-6. PubMed ID: 27279008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of biweekly chemotherapy with docetaxel and cisplatin in high-risk patients with unresectable non-small cell lung cancer.
    Kim MJ; Kim SH; Kang JH; Kim HG; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim MG; Choi JY; Lee GW
    Chemotherapy; 2013; 59(3):159-66. PubMed ID: 24107481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
    Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
    Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
    Herbst RS; Baas P; Kim DW; Felip E; Pérez-Gracia JL; Han JY; Molina J; Kim JH; Arvis CD; Ahn MJ; Majem M; Fidler MJ; de Castro G; Garrido M; Lubiniecki GM; Shentu Y; Im E; Dolled-Filhart M; Garon EB
    Lancet; 2016 Apr; 387(10027):1540-1550. PubMed ID: 26712084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice.
    Calpe-Armero P; Ferriols-Lisart R; Ferriols-Lisart F; Pérez-Pitarch A
    Chemotherapy; 2017; 62(6):374-380. PubMed ID: 29045938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition.
    Jiang Y; Yang N; Zhang H; Sun B; Hou C; Ji C; Zheng J; Liu Y; Zuo P
    J Control Release; 2016 Jan; 221():26-36. PubMed ID: 26643616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gelatinase-stimuli strategy enhances the tumor delivery and therapeutic efficacy of docetaxel-loaded poly(ethylene glycol)-poly(ɛ-caprolactone) nanoparticles.
    Liu Q; Li RT; Qian HQ; Yang M; Zhu ZS; Wu W; Qian XP; Yu LX; Jiang XQ; Liu BR
    Int J Nanomedicine; 2012; 7():281-95. PubMed ID: 22287839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab-conjugated PLGA nanoparticles as a prospective targeting therapeutics for non-small cell lung cancer.
    Kumari L; Ehsan I; Mondal A; Al Hoque A; Mukherjee B; Choudhury P; Sengupta A; Sen R; Ghosh P
    J Drug Target; 2023 Jun; 31(5):521-536. PubMed ID: 37010248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.